AneuRx Is First Sec. 522 Study Ordered Under Proposed Rule; More To Follow
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's AneuRx abdominal aortic aneurysm (AAA) endovascular graft will aim to compare long-term outcomes of the device's IDE cohort with patients who received the implant postmarket.
You may also be interested in...
Medtronic Cited For Late Postmarket Report; First “522” Action Under FDAMA
An FDA 1warning letter sent to Medtronic Sept. 27 is the agency's first enforcement action under its 1997 powers to compel device makers to collect specified postmarket surveillance data
Medtronic Cited For Late Postmarket Report; First “522” Action Under FDAMA
An FDA 1warning letter sent to Medtronic Sept. 27 is the agency's first enforcement action under its 1997 powers to compel device makers to collect specified postmarket surveillance data
IoM Pediatric Report Calls For Congressional Action, Better Collaboration
Improving FDA postmarket surveillance capabilities will require congressional intervention in addition to other non-legislative measures, an Institute of Medicine report on pediatric device regulation issued July 18 suggests